← Eichor
Study identifier: NCT05407636 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

Condition: AMD · nAMD · Wet Age-related Macular Degeneration  ·  Sponsor: AbbVie

PhasePhase 3
Planned participants714
Who can joinAll sexes, 50 Years to 89 Years
Healthy volunteersNo

About this study

ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every four to 12 weeks in frequency, to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time. ABBV-RGX-314 is being developed as a potential one-time treatment for wet AMD.

This description comes directly from the study's public registry record.

Talk to the study team

Patient Advocacy  ·  1-833-711-0349  ·  Patientadvocacy@regenxbio.com

Always discuss trial participation with your own doctor first.

Locations (181)

Barnet Dulaney Eye Center-Phoenix /ID# 256340Phoenix, Arizona, United StatesRecruiting
Retinal Research Institute /ID# 256238Phoenix, Arizona, United StatesRecruiting
Retina Macula Institute of Arizona /ID# 271026Scottsdale, Arizona, United StatesRecruiting
California Retina Consultants - Bakersfield /ID# 256240Bakersfield, California, United StatesRecruiting
Retina Vitreous Assoc Med Grp /ID# 256246Beverly Hills, California, United StatesRecruiting
Retinal Diagnostic Center /ID# 256262Campbell, California, United StatesRecruiting
The Retina Partners - Encino /ID# 259660Encino, California, United StatesRecruiting
Retina Consultants of Orange County /ID# 256267Fullerton, California, United StatesActive Not Recruiting
Jacobs Retina Center at UCSD/ID# 256320La Jolla, California, United StatesActive Not Recruiting
California Retina Consultants - Oxnard - North Ventura Road /ID# 262883Oxnard, California, United StatesRecruiting
Byers Eye Institute Stanford /ID# 262853Palo Alto, California, United StatesRecruiting
Retina Consultants of San Diego /ID# 256258Poway, California, United StatesActive Not Recruiting

+ 169 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05407636